{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:43:39Z","timestamp":1773157419412,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T00:00:00Z","timestamp":1319068800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2407-11-453","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T19:56:37Z","timestamp":1320263797000},"source":"Crossref","is-referenced-by-count":31,"title":["The PACOVAR-trial: A phase I\/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Michael","family":"Eichbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Bischofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christian","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Fersis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,20]]},"reference":[{"key":"2930_CR1","unstructured":"GEKID-Atlas: Inzidenz und Mortalit\u00e4t von Krebserkrankungen in den Bundesl\u00e4ndern. [ http:\/\/www.ekr.med.uni-erlangen.de\/GEKID\/Atlas\/CurrentVersion\/Inzidenz\/atlas.html ]"},{"key":"2930_CR2","unstructured":"GEKID-Atlas: Inzidenz und Mortalit\u00e4t von Krebserkrankungen in den Bundesl\u00e4ndern. [ http:\/\/www.ekr.med.uni-erlangen.de\/GEKID\/Atlas\/CurrentVersion\/Mortalitaet\/atlas.html ]"},{"key":"2930_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1023\/A:1008303300675","volume":"10","author":"WP McGuire","year":"1999","unstructured":"McGuire WP, Brady MF, Ozols RF: The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol. 1999, 10: 29-34.","journal-title":"Ann Oncol"},{"key":"2930_CR4","first-page":"477","volume-title":"Amer Soc Clin Oncol Educational Book","author":"WP McGuire","year":"2001","unstructured":"McGuire WP: Primary therapy of epithelial ovarian cancer. Amer Soc Clin Oncol Educational Book. 2001, Spring, 477-480."},{"issue":"9375","key":"2930_CR5","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003, 361 (9375): 2099-106.","journal-title":"Lancet"},{"issue":"2","key":"2930_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60","author":"N Colombo","year":"2006","unstructured":"Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I: Ovarian cancer. Crit Rev Oncol Hematol. 2006, 60 (2): 159-79. 10.1016\/j.critrevonc.2006.03.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2930_CR7","first-page":"427","volume":"7","author":"S Gately","year":"2001","unstructured":"Gately S, Kerbel R: Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer. 2001, 7: 427-436.","journal-title":"Cancer"},{"key":"2930_CR8","first-page":"2731","volume":"62","author":"S Man","year":"2002","unstructured":"Man S, Bocci G, Francia G, et al: Antitumor effects in mice of low dose (metronomic) cyclyophoshphamide administered continuously through the drinking water. Cancer Res. 2002, 62: 2731-2735.","journal-title":"Cancer Res"},{"key":"2930_CR9","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1073\/pnas.2135406100","volume":"100","author":"G Bocci","year":"2003","unstructured":"Bocci G, Francia G, Man S, et al: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA. 2003, 100: 12917-12922,. 10.1073\/pnas.2135406100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2930_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri T, et al: Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002, 13: 73-80. 10.1093\/annonc\/mdf013.","journal-title":"Ann Oncol"},{"key":"2930_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2407-7-65","volume":"7","author":"R Samaritini","year":"2001","unstructured":"Samaritini R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide \"metronomic\" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer. 2001, 7: 65-","journal-title":"BMC Cancer"},{"key":"2930_CR12","first-page":"501","volume":"61","author":"L Bello","year":"2001","unstructured":"Bello L, Carrabba G, Giussani C, et al: Low dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001, 61: 501-506.","journal-title":"Cancer Res"},{"key":"2930_CR13","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G, Baruchel S, Rak J, et al: Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000, 105: R15-24. 10.1172\/JCI8829.","journal-title":"J Clin Invest"},{"key":"2930_CR14","first-page":"221","volume":"8","author":"G Klement","year":"2002","unstructured":"Klement G, Huang P, Mayer B, et al: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-vegfr-2 antibody in multidrug resistant human breastcancer xenografts. Clin Cancer Res. 2002, 8: 221-232.","journal-title":"Clin Cancer Res"},{"key":"2930_CR15","first-page":"846","volume":"61","author":"N Takahashi","year":"2001","unstructured":"Takahashi N, Haba A, Matsuno F, et al: Antiangiogenic therapy of established tumors in human skin\/severe combined immunodeficiency mouse chimeras by antiendoglin (CD105) monoclonal antibodies and synergy between antiendoglin antibody and cyclophosphamide. Cancer Res. 2001, 61: 846-854.","journal-title":"Cancer Res"},{"key":"2930_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","volume":"107","author":"JC Chura","year":"2007","unstructured":"Chura JC, Van Iseghem K, Downs LS, et al: Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007, 107: 326-30. 10.1016\/j.ygyno.2007.07.017.","journal-title":"Gynecol Oncol"},{"key":"2930_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008, 26: 76-82. 10.1200\/JCO.2007.12.1939.","journal-title":"J Clin Oncol"},{"key":"2930_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","volume":"10","author":"JM Jurado Garc\u00eda","year":"2008","unstructured":"Jurado Garc\u00eda JM, S\u00e1nchez A, Pajares B, P\u00e9rez E, Alonso L, Alba E: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol. 2008, 10: 583-6. 10.1007\/s12094-008-0254-7.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2930_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1 (1): 27-31. 10.1038\/nm0195-27.","journal-title":"Nat Med"},{"issue":"4","key":"2930_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ncponc1051","volume":"5","author":"WA Spannuth","year":"2008","unstructured":"Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008, 5 (4): 194-204.","journal-title":"Nat Clin Pract Oncol"},{"key":"2930_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82: 4-6. 10.1093\/jnci\/82.1.4.","journal-title":"J Natl Cancer Inst"},{"key":"2930_CR22","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L: Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res. 2009, 15: 4220-4227. 10.1158\/1078-0432.CCR-08-2740.","journal-title":"Clin Cancer Res"},{"key":"2930_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in Locally Advanced or Metastatic Renal Cell: Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2010, 28: 1061-1068. 10.1200\/JCO.2009.23.9764.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2930_CR24","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009, 27 (19): 3126-32. 10.1200\/JCO.2008.21.3223.","journal-title":"J Clin Oncol"},{"key":"2930_CR25","first-page":"1233","volume-title":"ESMO Congress","author":"D Slamon","year":"2008","unstructured":"Slamon D, Gomez H, Amit O, Richie M, Pandite L, Roychowdhury D, Goodman V: Updated Results From a Randomized Study in Patients With First-line ErbB2-positive Advanced or Metastatic Breast Cancer. ESMO Congress. 2008, 1233-[abstract]"},{"issue":"19","key":"2930_CR26","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1200\/JCO.2009.23.9749","volume":"28","author":"N Altorki","year":"2010","unstructured":"Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF: Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I\/II resectable non-small-cell lung cancer. J Clin Oncol. 2010, 28 (19): 3131-7. 10.1200\/JCO.2009.23.9749.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2930_CR27","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010, 28 (22): 3562-9. 10.1200\/JCO.2009.26.9571.","journal-title":"J Clin Oncol"},{"key":"2930_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","volume":"119","author":"M Friedlander","year":"2010","unstructured":"Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ: A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010, 119: 32-37. 10.1016\/j.ygyno.2010.05.033.","journal-title":"Gynecol Oncol"},{"key":"2930_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R: Optimal two-stage designs for phase II clinical trials. Contr Clin Trials. 1989, 10: 1-10. 10.1016\/0197-2456(89)90015-9.","journal-title":"Contr Clin Trials"},{"key":"2930_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780141102","volume":"14","author":"SN Goodman","year":"1995","unstructured":"Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995, 14: 1149-61. 10.1002\/sim.4780141102.","journal-title":"Stat Med"},{"key":"2930_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","volume":"21","author":"GJS Rustin","year":"2003","unstructured":"Rustin GJS: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003, 21: 187-203. 10.1200\/JCO.2003.01.223.","journal-title":"J Clin Oncol"},{"key":"2930_CR32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","volume":"95","author":"T Levy","year":"2004","unstructured":"Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004, 95: 686-90. 10.1016\/j.ygyno.2004.09.005.","journal-title":"Gynecol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-453\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T20:14:16Z","timestamp":1468354456000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2930"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-453","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]},"article-number":"453"}}